Pui J. Lam
London, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Real-world outcomes of triplet therapy with gilteritinib, azacitidine and venetoclax in FMS-like tyrosine kinase 3 (FLT3)-mutated relapsed/refractory acute myeloid leukaemia: A UK single-centre experience.
Journal: British journal of haematology
Published: April 14, 2026
Glofitamab in refractory Burkitt lymphoma-type post-transplant lymphoproliferative disorder.
Journal: British journal of haematology
Published: February 09, 2026
Nodal Peripheral T-Cell Lymphoma: Therapeutic Challenges and Future Perspectives.
Journal: Cancers
Published: February 17, 2025
Frailty subgroup analysis of isatuximab with pomalidomide and dexamethasone in a UK-wide real-world cohort of relapsed myeloma patients.
Journal: British journal of haematology
Published: December 11, 2022
Antibody drug conjugates for the treatment of multiple myeloma.
Journal: American journal of hematology
Published: July 15, 2022
Infections in relapsed myeloma patients treated with isatuximab plus pomalidomide and dexamethasone during the COVID-19 pandemic: Initial results of a UK-wide real-world study.
Journal: Hematology (Amsterdam, Netherlands)
Published: June 06, 2022
Impaired humoral and T cell response to vaccination against SARS-CoV-2 in chronic myeloproliferative neoplasm patients treated with ruxolitinib.
Journal: Blood cancer journal
Published: January 28, 2022
Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia.
Journal: British journal of haematology
Published: April 13, 2021
Showing 1-10 of 10
Last Updated: 09/26/2026